Nantes, France – October 20, 2022, 6 p.m. – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), provides an update on Tedopi®, an immunotherapy for the activation of specific T lymphocytes against cancer cells, developed in advanced or metastatic non-small cell lung cancer (NSCLC), in ovarian cancer and pancreatic cancer. Compassionate access authorizations* have been granted to Tedopi® in NSCLC by health authorities in Europe. Meetings are scheduled with regulatory agencies to validate the new protocol for the Phase 3 confirmatory clinical trial in NSCLC.